Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition
Under the definitive agreement, Italian pharmaceutical group will buy all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash.
Biopharmaceutical Industry
Moderna opens new manufacturing and R&D facility in the UK
Moderna opens Southern Hemisphere’s only mRNA manufacturing facility in Victoria
MilliporeSigma invests $290m in biosafety facility in Maryland
Schott Pharma to build syringe plant in US
Cytek opens new manufacturing plant in Wuxi, China
Inflation drives pharma manufacturing to focus on sustainability
